![Page 1: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/1.jpg)
CYBERKNIFE SRS & SBRT
P.Mahadev MD DNB
Apollo Speciality Cancer Hospital
Chennai
![Page 2: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/2.jpg)
MANAGEMENT AND DELIVERY OF IMAGE GUIDED HIGH DOSE RADIATION THERAPY WITH TUMOR ABLATIVE INTENT WITHIN A COURSE OF TREATMENT THAT DOES NOT EXCEED 5 DAYS
![Page 3: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/3.jpg)
Higher confidence in tumor targeting
Reliable mechanisms for generating focused, sharply delineated dose distributions with a rapid dose fall off
Reliable accurate patient positioning accounting for target motion related to time dependent organ movement
IMAGE GUIDANCE AND EFFICIENT TRACKING MECHANISM
Longer times than conventional RT, hence patient comfort is an issue
![Page 4: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/4.jpg)
SRSSBRTIMRT FOR PROSTATESRT
![Page 5: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/5.jpg)
![Page 6: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/6.jpg)
5
1
2
3
465
![Page 7: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/7.jpg)
PitchRollYaw
![Page 8: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/8.jpg)
Robot is capable of delivering radiation from different 100 nodes, with each node is capable of giving a maximum 12 different beams.
Usage of these nodes depends on the treatment room constraints
![Page 9: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/9.jpg)
![Page 10: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/10.jpg)
The table consists of 12 fixed cones and housings of Fixed and Iris Collimator
Collimator sizes(mm): 5, 7.5, 10, 12.5, 15, 20, 25, 30, 35, 40, 50, 60
Laser Sensor
![Page 11: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/11.jpg)
![Page 12: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/12.jpg)
![Page 13: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/13.jpg)
There are two essential features of the CyberKnife system that sets it apart from other stereotactic radiosurgery methods.
![Page 14: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/14.jpg)
radiation source is mounted on a precisely controlled industrial robot.
The image guidance system(continuous tracking system)
Eliminates the need of gating techniques and restrictive head frames
![Page 15: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/15.jpg)
The Cyberknife treatment delivery is based on the following tracking systems
6D_ Skull tracking systemFiducials tracking systemSynchrony tracking systemX_sight Spine tracking systemX_sight Lung tracking system
![Page 16: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/16.jpg)
6D_ Skull tracking system:used for intra-cranial lesions up to C2Bony anatomy of the skull is used as reference for tracking
![Page 17: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/17.jpg)
![Page 18: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/18.jpg)
Fiducial tracking system:used for soft tissues, where gold fiducials can be implanted. Minimum of 3 nos. to be implanted
![Page 19: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/19.jpg)
close proximity to the lesion to be treated
well-separated (by about 1 cm) non-overlapping on projections from the in-room x-ray imagers
Three markers are sufficient for unique spatial localization, but in practice 4-5 are often placed in case of loss or suboptimal placement of markers
![Page 20: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/20.jpg)
![Page 21: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/21.jpg)
• 790 fiducials• 85% successfully placed• 2 Patients developed
pneumothorax• 6 fiducials migrated- 3 in
lung, 2 in liver& 1 in prostate
![Page 22: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/22.jpg)
![Page 23: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/23.jpg)
![Page 24: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/24.jpg)
![Page 25: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/25.jpg)
![Page 26: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/26.jpg)
![Page 27: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/27.jpg)
![Page 28: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/28.jpg)
![Page 29: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/29.jpg)
![Page 30: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/30.jpg)
![Page 31: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/31.jpg)
![Page 32: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/32.jpg)
Respiratory-induced motion of tumors causes significant targeting uncertainty Lung, liver, pancreas, Prostate,kidney
Traditional radiation therapy margins are not optimized for high-dose radiosurgery
![Page 33: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/33.jpg)
![Page 34: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/34.jpg)
Imaging and Tumor TargetingTraditional IGRT daily set-up imaging maybe inadequate for sub-millimeter accuracy
ImmobilizationBreath Holding
![Page 35: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/35.jpg)
Imaging and Tumor TargetingTraditional IGRT daily set-up imaging maybe inadequate for sub-millimeter accuracy
ImmobilizationBreath HoldingGating
![Page 36: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/36.jpg)
option for dynamic tracking without the use of implanted fiducials.
Tumor localization is accomplished using auto- mated real-time image segmentation of the in-room x-ray images based on the contrast of the tumor itself.
![Page 37: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/37.jpg)
best used for lesions with sufficient contrast in density from the surrounding anatomy to be clearly visualized on both of the in-room x-ray imagers, i.e., those located in the lung periphery at least 1.5 cm in size, and that do not overlap other dense anatomical structures, such as the spine, diaphragm, and heart in the projection views
![Page 38: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/38.jpg)
Two features to form the basis for accuracy
Fiducials, implanted prior to treatment
Optical markers on a special patient vest
![Page 39: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/39.jpg)
Prior to treatment start: creation of dynamic correlation model
Markers are monitored in real time by a camera system
Imaging system takes positions of fiducials at discrete points of time
![Page 40: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/40.jpg)
Prior to treatment start: creation of dynamic correlation model
Markers are monitored in real time by a camera system
Imaging system takes positions of fiducials at discrete points of time
time
disp
lace
men
t
disp
lace
men
t
time
![Page 41: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/41.jpg)
This process repeats throughout the treatment, updating and correcting beam delivery based upon the patient’s current breathing pattern
time
disp
lace
men
t
disp
lace
men
t
time
![Page 42: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/42.jpg)
![Page 43: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/43.jpg)
![Page 44: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/44.jpg)
![Page 45: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/45.jpg)
![Page 46: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/46.jpg)
![Page 47: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/47.jpg)
X-sight Spine tracking system:used to track spine lesions which are close to spine from C1 to L5&sacrum
Uses the bony anatomy of spine to track the tumors in close relation to spine eliminating the need for fiducials
X-sight spine is now possible in prone position as well
![Page 48: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/48.jpg)
![Page 49: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/49.jpg)
The appropriate tracking method has to be chosen during planning itself
No treatment is possible without planning and proper tracking method
![Page 50: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/50.jpg)
Treatment planning is done on the CT images of slice thickness 1mm acquired at 125 kV and 400 mAs with a pixel size of 512 x 512
MRI, PET and 3D-Angio images can be used to fuse with the primary CT images for target and OAR delineation
![Page 51: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/51.jpg)
Planning System (MultiPlan) uses inverse planning algorithm with following options1. Conformal Planning2. Sequential optimizationThe system provides the user the option of using either ray tracing method or Monte Carlo
![Page 52: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/52.jpg)
The mechanical accuracy of the system is 0.12 mm , according to Accuray
The system maintains sub-millimeter tracking accuracy, if the patient positions are within the following limitsLeft / Right (Lat) 10 mmAnt/ Post (Ver) 10 mmSup/ Inf ( Long) 10 mmRoll (Left / Right) 10
Pitch (Head Up / Down) 10
Yaw ( C.W / C.C.W) 30
![Page 53: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/53.jpg)
The Robot will correct its position if the off set values are with in the specified limits
The robot will trigger an Emergency Stop outside of these tolerances
![Page 54: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/54.jpg)
![Page 55: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/55.jpg)
![Page 56: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/56.jpg)
![Page 57: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/57.jpg)
![Page 58: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/58.jpg)
Gamma knife, X-knife are probably as good.
May have an advantage for larger lesions requiring multiple fractions- meningioma, acoustic schwanomma etc
More patient friendly(frame)Continuous image guidance
![Page 59: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/59.jpg)
T1&T2 NSCLC – inoperable or medical contraindication or patient refuses surgery, ideal lesion <3cm & peripheral location
oligometastasis
![Page 60: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/60.jpg)
![Page 61: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/61.jpg)
![Page 62: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/62.jpg)
![Page 63: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/63.jpg)
![Page 64: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/64.jpg)
![Page 65: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/65.jpg)
in a uniform population of medically inoperable patients with peripherally located early lung cancer, the RTOG 0236 study dem- onstrated 98% local control (within the primary tumor) and 87% local-regional control (within the ipsilateral lobe, hilum, and mediastinum) at 3 years with an intensive regimen of 60 Gy in 3 fractions
![Page 66: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/66.jpg)
![Page 67: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/67.jpg)
RADIOBIOLOGICAL RATIONALE: LOW APLHA/BETA RATIO
GOOD RESULTS OBTAINED WITH HDR brachytherapy
LESS INVASIVE THAN BRACHYTHERAPY
![Page 68: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/68.jpg)
![Page 69: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/69.jpg)
![Page 70: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/70.jpg)
![Page 71: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/71.jpg)
Ju AW et al :Radiat oncol jan201341 pts intermediate riskMedian fu 21 mo99% biochemical PFSNo gr3/4 bladder or bowel morbidityNo significant change in sexual QOL
![Page 72: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/72.jpg)
![Page 73: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/73.jpg)
![Page 74: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/74.jpg)
![Page 75: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/75.jpg)
BRACHYTHERAPY: 10/10.5 Gy x3 over 24 hours, each fraction 8 hours apart
BED : 130/142 GySBRT : 7.25 Gy x5 over 5 daysBED: 123 Gy
![Page 76: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/76.jpg)
T1 T2 PSA<10 PSA>10 GS<7 GS>7 TOTAL
HDR 30 22 35 17 40 12 52
CK 34 32 40 16 35 31 66
IMRT/IGRT
94 186 94 186 126 154 280
![Page 77: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/77.jpg)
MEDIAN FU 2 YR BIOCHEMICAL PFS
MEDIAN PSA NADIR
HDR 22 MONTHS 94% 0.8
CK 16 MONTHS 96% 1.0
IMRT/IGRT 48 MONTHS 89% 0.9
![Page 78: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/78.jpg)
![Page 79: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/79.jpg)
![Page 80: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/80.jpg)
Fiducials placed at surgeryOne planning CT with oral and IV contrast
1000cGy to +ve margins 3-4 weeks post OP
5040cGy 5-6 field IMRT6-8 weeks postOPConcurrent XelodaAdjuvant Gemcitabine
![Page 81: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/81.jpg)
![Page 82: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/82.jpg)
![Page 83: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/83.jpg)
![Page 84: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/84.jpg)
![Page 85: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/85.jpg)
![Page 86: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/86.jpg)
![Page 87: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/87.jpg)
![Page 88: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/88.jpg)
Intramedullary spinal cord AVM’s onlyNot amenable to microsurgical excision/embolisation
symptomatic
![Page 89: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/89.jpg)
Neurologic examinationMRIConventional 2D spinal angio
![Page 90: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/90.jpg)
Spine tracking1.25 mm contrast enhanced axial CTTarget volume traced on CT in cojunction with:MRI
2D/3D spinal angio
![Page 91: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/91.jpg)
24 patients15 males 9 femalesTime from diagnosis to SRS:7.8 yrsMean age at SRS 34 YrsPresentation :12 hemorrhages
12 had progressive pain or myelopathy secondary to steal or venous congestion
![Page 92: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/92.jpg)
13 cervical8 thoracic3 conus medullaris
![Page 93: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/93.jpg)
Target volume :2.8cc(0.26-15 cc)Marginal nidus dose :2050cGy(1600-2100)
Prescription isodose line:79%(68-90%)Dmax:2580cGyFractions:1 to 4
![Page 94: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/94.jpg)
Angiographic outcome:significant AVM reduction in all patients >1yr post SRS
6 of 19 patients obliterateNo angio done in 5 patientsClinical outcome:no further hemorrhages
![Page 95: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/95.jpg)
![Page 96: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/96.jpg)
![Page 97: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/97.jpg)
3 PATIENTS28 YRS OLD LADY EMBOLISATION DONE TWICE PRESENTED WITH SEVERE PAIN IN THE POPLITEAL FOSSA AND CALF REGION
56 YEARS OLD LADY WITH SUDDEN ONSET OF MYELOPATHY
BOTH THE PATIENTS RESPONDED WELL25 yr old young man, repeated embolisations done,had no improvement
![Page 98: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/98.jpg)
![Page 99: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/99.jpg)
![Page 100: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/100.jpg)
Current prescription dose to nidus is 2000 cGy in 2 sessions to larger lesions & 16-18 Gy for small (<0.7 cc) AVM
radiosurgery is a reasonable option in most type II spinal cord AVMs
![Page 101: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/101.jpg)
Gerszten et al., Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution Volume 32,
Number 2, pp 193–199, 2007
500 cases of spinal metastases treated by CyberKnife® Radiosurgery at
the University of Pittsburgh
73 cervical, 212 thoracic, 112 lumbar, and 103 sacral lesions
Long-term pain improvement occurred in 290 of 336 cases (86%)
Long-term tumor control in 90% of lesions treated with radiosurgery as a primary treatment modality
Long-term tumor control in 88% of lesions that failed other therapies
![Page 102: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/102.jpg)
Stereotactic radiosurgery is not a substitute to surgery but an alternative when indicated
SBRT is becoming a component in the multidisciplinary treatment of Cancer
In selected cases, SBRT may prove to be a curative modality of treatment in early cancers
![Page 103: Apollo hydbd feb8 2013 (cancer ci 2013) p. mahadev md](https://reader038.vdocuments.site/reader038/viewer/2022110120/557c6235d8b42a64778b4f1e/html5/thumbnails/103.jpg)